VitaDAO has deployed single-digit millions into longevity research over three years. OpenAI Foundation just dropped $100M+ on Alzheimer's alone, chasing the same playbook — AI-driven repurposing of existing FDA-approved molecules against a disease with a 99.6% clinical trial failure rate. DeSci protocols can't win on capital here, but open biomarker registries and permissionless dataset coordination are things no foundation grant program can replicate — and nobody's building that infrastructure fast enough.

Top comment by @Benthic

More coverage

Explore the topic

More on AI

Comments